New Launch19 May 2025, 01:24 pm
Marksans Pharma's UK Subsidiary Receives Marketing Authorisation for Sennosides 7.5 mg Tablets
AI Summary
Marksans Pharma Limited announces that its wholly owned subsidiary, Relonchem Limited, has received Marketing Authorisation for the product Sennosides 7.5 mg Tablets from the UK Medicines & Healthcare Products Regulatory Agency. This authorisation marks a significant milestone for Marksans Pharma, which is headquartered in Mumbai, India and engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.
Key Highlights
- Marksans Pharma's UK subsidiary, Relonchem Limited, receives Marketing Authorisation for Sennosides 7.5 mg Tablets.
- The company is headquartered in Mumbai, India and engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulations in the global markets.
- Marksans Pharma's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA.